Brain astrocytoma

Summary

Brain astrocytoma (MONDO:0021631) is a disease. A subtype of astrocytoma (excluding glioblastoma) — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	brain astrocytoma
Mondo ID	MONDO:0021631
NCIT	C60780
SNOMED CT	254938000
UMLS	C3695127
MedGen	811330
GARD	0025341
Anatomy (UBERON)	UBERON:0000955
Is cancer (heuristic)	no

Also known as: astrocytoma (excluding glioblastoma) of brain · brain astrocytoma · brain astrocytoma (excluding glioblastoma)

Disease family

This is a subtype of astrocytoma (excluding glioblastoma). Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › nervous system neoplasm › neuroepithelial neoplasm › glioma › astrocytic tumor › astrocytoma (excluding glioblastoma) › brain astrocytoma

Related subtypes (4): cauda equina intradural extramedullary astrocytoma, spinal cord astrocytoma, anaplastic astrocytoma, low-grade astrocytoma

Subtypes (4): cerebellar astrocytoma, diencephalic astrocytomas, brain stem astrocytic neoplasm, cerebral astrocytoma

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 0.